Updates are available Correction dated 2023-01-17
Click to view Correction: https://doi.org/10.1038/s41467-023-35831-7
-
Authors
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SCHU 2494/3-1, SCHU 2494/7-1, SCHU 2494/11-1, CECAD EXC 2030 – 390661388, SFB 829, SFB 670, KFO 286, KFO 329, GRK 2407, SCHU 2494/10-1)
Deutsche Krebshilfe (70112899)
EC | Horizon 2020 Framework Programme (H2020-MSCA-ITN-2018 Healthage, H2020-MSCA-ITN-2018 ADDRESS)
John Templeton Foundation (61734)
- License Information
-
More Information
Article History
Received: 20 July 2021
Accepted: 8 January 2022
First Online: 4 February 2022
Change Date: 17 January 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-023-35831-7
Competing interests
: B.S. is co-founder of Agevio Therapeutics, Inc. All authors declare no other competing interests.
